Gambaran Umum
ImmuCell Corporation is a U.S.-based biotechnology company primarily engaged in the development, manufacture, and sale of bovine health products that provide significant solutions to dairy and beef producers. The company, headquartered in Portland, Maine, specializes in products that improve the health and productivity of dairy and beef cattle without using antibiotics. One of ImmuCell's key projects includes the development of its flagship product, First Defense, an innovative, non-antibiotic preventative solution against scours (diarrhea) in newborn calves. This product embodies the company's commitment to delivering immediate immunity, enhancing animal health, and addressing consumer demands for antibiotic stewardship in food production. ImmuCell's focus on practical and sustainable veterinary solutions underscores its contribution to advancing animal health technology within the agricultural sector.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk ImmuCell Corporation per 2025 Jun 30 adalah 28.27 MM.
- Nilai operating income untuk ImmuCell Corporation per 2025 Jun 30 adalah 2.14 MM.
- Nilai net income untuk ImmuCell Corporation per 2025 Jun 30 adalah 1.76 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 28.27 | 2.14 | 1.76 |
2025-03-31 | 27.30 | 0.18 | -0.27 |
2024-12-31 | 26.49 | -1.23 | -2.16 |
2024-09-30 | 23.84 | -2.74 | -3.81 |
2024-06-30 | 23.22 | -3.35 | -4.05 |
2024-03-31 | 21.28 | -3.27 | -3.90 |
2023-12-31 | 17.47 | -5.22 | -5.77 |
2023-09-30 | 16.29 | -5.79 | -6.30 |
2023-06-30 | 15.69 | -5.22 | -6.02 |
2023-03-31 | 16.01 | -4.54 | -5.32 |
2022-12-31 | 18.57 | -1.71 | -2.49 |
2022-09-30 | 20.10 | -0.52 | -0.75 |
2022-06-30 | 20.46 | 0.37 | 0.05 |
2022-03-31 | 21.14 | 1.20 | 0.88 |
2021-12-31 | 19.24 | 0.26 | -0.08 |
2021-09-30 | 17.54 | -0.52 | 0.04 |
2021-06-30 | 16.11 | -1.05 | -0.43 |
2021-03-31 | 14.54 | -1.95 | -1.34 |
2020-12-31 | 15.34 | -1.38 | -1.02 |
2020-09-30 | 15.23 | -0.99 | -1.52 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk ImmuCell Corporation pada 2025 Jun 30 adalah 0.20.
- laba per saham yang terdilusi untuk ImmuCell Corporation pada 2025 Jun 30 adalah 0.21.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | 0.20 | 0.21 |
2025-03-31 | -0.03 | -0.03 |
2024-12-31 | -0.26 | -0.26 |
2024-09-30 | -0.48 | -0.49 |
2024-06-30 | -0.52 | -0.52 |
2024-03-31 | -0.50 | -0.51 |
2023-12-31 | -0.75 | -0.75 |
2023-09-30 | -0.81 | -0.81 |
2023-06-30 | -0.78 | -0.78 |
2023-03-31 | -0.69 | -0.69 |
2022-12-31 | -0.32 | -0.32 |
2022-09-30 | -0.10 | -0.10 |
2022-06-30 | 0.01 | 0.01 |
2022-03-31 | 0.11 | 0.12 |
2021-12-31 | -0.01 | -0.01 |
2021-09-30 | 0.00 | 0.01 |
2021-06-30 | -0.06 | -0.06 |
2021-03-31 | -0.19 | -0.18 |
2020-12-31 | -0.14 | -0.14 |
2020-09-30 | -0.21 | -0.21 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk ImmuCell Corporation per 2025 Jun 30 adalah 2.53 MM.
- Nilai cash from investing activities untuk ImmuCell Corporation per 2025 Jun 30 adalah -0.74 MM.
- Nilai kas dari aktivitas pendanaan untuk ImmuCell Corporation per 2025 Jun 30 adalah 2.88 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | 2.53 | -0.74 | 2.88 |
2025-03-31 | 1.51 | -0.72 | 2.85 |
2024-12-31 | 0.36 | -0.46 | 2.88 |
2024-09-30 | -0.36 | -0.23 | 2.41 |
2024-06-30 | -0.23 | -0.68 | 0.78 |
2024-03-31 | -1.49 | -1.28 | 0.64 |
2023-12-31 | -4.67 | -1.89 | 1.75 |
2023-09-30 | -5.25 | -3.41 | 1.82 |
2023-06-30 | -6.00 | -3.62 | 0.03 |
2023-03-31 | -4.94 | -3.85 | 0.07 |
2022-12-31 | -1.54 | -3.96 | 1.11 |
2022-09-30 | 0.34 | -3.18 | 1.17 |
2022-06-30 | 1.86 | -3.11 | 1.60 |
2022-03-31 | 2.22 | -3.05 | 5.84 |
2021-12-31 | 0.95 | -1.60 | 3.88 |
2021-09-30 | 0.52 | -0.14 | 4.79 |
2021-06-30 | -0.40 | -0.94 | 4.44 |
2021-03-31 | -0.17 | -2.63 | 1.69 |
2020-12-31 | 1.32 | -2.57 | 1.91 |
2020-09-30 | 1.11 | 0.88 | 0.98 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk ImmuCell Corporation pada 2025 Jun 30 adalah 2.17.
- p/tbv untuk ImmuCell Corporation pada 2025 Jun 30 adalah 2.17.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 2.17 | 2.17 | |
2025-03-31 | 1.69 | 1.70 | |
2024-12-31 | 1.63 | 1.63 | |
2024-09-30 | -6.87 | 1.19 | 1.19 |
2024-06-30 | -9.57 | 1.51 | 1.52 |
2024-03-31 | 1.58 | 1.59 | |
2023-12-31 | -6.26 | 1.52 | 1.52 |
2023-09-30 | -6.87 | 1.54 | 1.55 |
2023-06-30 | -7.26 | 1.37 | 1.38 |
2023-03-31 | 0.00 | 0.00 | |
2022-12-31 | -62.86 | 1.48 | 1.48 |
2022-09-30 | 1.82 | 1.83 | |
2022-06-30 | 2.01 | 2.02 | |
2022-03-31 | -962.77 | 2.31 | 2.31 |
2021-12-31 | 1,701.34 | 1.91 | 1.92 |
2021-09-30 | -166.87 | 2.25 | 2.26 |
2021-06-30 | |||
2021-03-31 | -46.36 | 2.23 | 2.25 |
2020-12-31 | -60.82 | 2.20 | 2.21 |
2020-09-30 | -40.82 | 2.22 | 2.23 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk ImmuCell Corporation pada 2025 Jun 30 adalah -0.00.
- EBIT (3 tahun) / EV untuk ImmuCell Corporation pada 2025 Jun 30 adalah -0.05.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.00 | -0.05 |
2025-03-31 | -0.04 | -0.07 |
2024-12-31 | -0.08 | -0.08 |
2024-09-30 | -0.11 | -0.10 |
2024-06-30 | -0.08 | -0.06 |
2024-03-31 | -0.11 | -0.05 |
2023-12-31 | -0.12 | -0.05 |
2023-09-30 | -0.12 | -0.04 |
2023-06-30 | -0.11 | -0.04 |
2023-03-31 | -0.00 | -0.00 |
2022-12-31 | -0.02 | -0.02 |
2022-09-30 | 0.00 | -0.01 |
2022-06-30 | 0.02 | -0.01 |
2022-03-31 | -0.00 | -0.01 |
2021-12-31 | 0.00 | -0.01 |
2021-09-30 | -0.01 | -0.02 |
2021-06-30 | ||
2021-03-31 | -0.02 | -0.02 |
2020-12-31 | -0.02 | -0.02 |
2020-09-30 | -0.02 | -0.02 |
Efektivitas Manajemen
- roa untuk ImmuCell Corporation pada 2025 Jun 30 adalah -0.01.
- roe untuk ImmuCell Corporation pada 2025 Jun 30 adalah -0.01.
- roic untuk ImmuCell Corporation pada 2025 Jun 30 adalah -0.01.
- croic untuk ImmuCell Corporation pada 2025 Jun 30 adalah 0.08.
- ocroic untuk ImmuCell Corporation pada 2025 Jun 30 adalah 0.03.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.01 | -0.01 | -0.01 | 0.08 | 0.03 |
2025-03-31 | -0.05 | -0.09 | -0.05 | 0.04 | -0.01 |
2024-12-31 | -0.09 | -0.15 | -0.09 | 0.04 | -0.01 |
2024-09-30 | -0.09 | -0.16 | -0.10 | -0.00 | -0.01 |
2024-06-30 | -0.09 | -0.14 | -0.10 | -0.05 | -0.04 |
2024-03-31 | -0.18 | -0.14 | -0.16 | -0.12 | |
2023-12-31 | -0.14 | -0.20 | -0.14 | -0.16 | -0.12 |
2023-09-30 | -0.13 | -0.18 | -0.14 | -0.23 | -0.14 |
2023-06-30 | -0.12 | -0.16 | -0.14 | -0.23 | -0.14 |
2023-03-31 | -0.05 | -0.07 | -0.00 | -0.00 | -0.00 |
2022-12-31 | -0.02 | -0.02 | -0.02 | -0.04 | 0.01 |
2022-09-30 | 0.01 | 0.01 | -0.02 | -0.04 | 0.01 |
2022-06-30 | 0.03 | 0.03 | 0.01 | 0.01 | 0.04 |
2022-03-31 | -0.00 | -0.00 | 0.03 | 0.15 | 0.06 |
2021-12-31 | 0.00 | 0.00 | -0.00 | 0.08 | 0.01 |
2021-09-30 | -0.01 | -0.02 | 0.00 | 0.12 | -0.01 |
2021-06-30 | -0.01 | -0.02 | -0.01 | 0.07 | -0.01 |
2021-03-31 | -0.03 | -0.05 | -0.03 | -0.03 | -0.00 |
2020-12-31 | -0.03 | -0.04 | -0.03 | 0.02 | 0.03 |
2020-09-30 | -0.04 | -0.05 | -0.04 | 0.08 | 0.03 |
Gross Margins
- marjin kotor untuk ImmuCell Corporation pada 2025 Jun 30 adalah 0.34.
- marjin bersih untuk ImmuCell Corporation pada 2025 Jun 30 adalah -0.01.
- marjin operasi untuk ImmuCell Corporation pada 2025 Jun 30 adalah 0.01.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.34 | -0.01 | 0.01 |
2025-03-31 | 0.30 | -0.08 | -0.06 |
2024-12-31 | 0.29 | -0.16 | -0.11 |
2024-09-30 | 0.28 | -0.17 | -0.14 |
2024-06-30 | 0.30 | -0.18 | -0.15 |
2024-03-31 | 0.22 | -0.33 | -0.33 |
2023-12-31 | 0.22 | -0.39 | -0.39 |
2023-09-30 | 0.23 | -0.38 | -0.37 |
2023-06-30 | 0.31 | -0.38 | -0.41 |
2023-03-31 | 0.41 | -0.33 | -0.31 |
2022-12-31 | 0.46 | -0.04 | -0.03 |
2022-09-30 | 0.48 | -0.04 | -0.03 |
2022-06-30 | 0.48 | 0.01 | 0.03 |
2022-03-31 | 0.45 | 0.05 | 0.07 |
2021-12-31 | 0.44 | -0.00 | 0.01 |
2021-09-30 | 0.44 | 0.00 | -0.03 |
2021-06-30 | 0.44 | -0.03 | -0.06 |
2021-03-31 | 0.43 | -0.09 | -0.13 |
2020-12-31 | 0.45 | -0.07 | -0.09 |
2020-09-30 | 0.46 | -0.10 | -0.06 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 811641 |
Grupong Pang-industriya
SIC 2835 - In Vitro and In Vivo Diagnostic Substances |